Our Company

Mr. Pauls has served as Chair of the Board of Directors and Chief Executive Officer of Savara since 2020. He is also currently Lead Independent Director on the Board of Directors of Soleno Therapeutics, a publicly traded biopharmaceutical company focused on rare diseases. Mr. Pauls also serves on the Board of Directors for two private companies; Amplo Biotechnology, a gene therapy company focused on rare neuromuscular disorders, and Pelthos Therapeutics, a biopharmaceutical company focused on dermatologic infectious diseases. From 2014 to 2019, Mr. Pauls was President and Chief Executive Officer and a member of the Board of Directors of Strongbridge Biopharma plc., a publicly traded rare disease focused biopharmaceutical company that he took public via IPO on the NASDAQ. Prior to 2014, he served as Chief Commercial Officer of Insmed, Inc., where he led both the global Commercial and Technical Operations organizations. Prior to Insmed, Mr. Pauls worked at Shire Pharmaceuticals, most recently as Senior Vice President, Head of Global Commercial Operations, and earlier in his career held senior commercial leadership positions at Bristol Myers Squibb and Johnson & Johnson. In addition to his other Board positions, Mr. Pauls has also served as Chair of the Board of Directors of Mast Therapeutics and was a member of the Board of Directors of Zyla Life Sciences, both publicly traded biopharma companies. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.

Ms. Erickson has served as Savara’s Chief Business Officer since August 2023 and is responsible for the Investor Relations, Corporate Affairs, Project Management, Advocacy Relations & Patient Engagement teams and leads corporate strategic projects. Since joining the company in October 2018, she’s held roles of increasing responsibility, including SVP of Global Business Operations, Chief of Staff, and Head of Investor Relations and Corporate Communications. Further, Anne led the Clinical Operations Team for the IMPALA-2 trial (from study start-up through the double-blind period) and was also Interim Head of Quality Assurance. Prior to Savara, she held leadership roles within corporate, consulting, and agency settings at various companies, including Mirati Therapeutics, Halozyme, Pfizer, and Ogilvy.

Mr. Lowrance has served as Savara’s Chief Financial and Administrative Officer since December 2022 and Chief Financial Officer since November 2016. Previously, Mr. Lowrance was the Chief Financial Officer and Treasurer of Edgemont Pharmaceuticals, a fully integrated specialty pharmaceutical company. Prior to that, Mr. Lowrance served as the Chief Financial Officer and Secretary of Acucela Inc., a clinical-stage biotechnology company, where he was responsible for overseeing all aspects of the day-to-day operations, business development and growth endeavors, investor relations, and corporate communications. While there, Mr. Lowrance helped lead a $162 million international IPO, with a listing on the Tokyo Stock Exchange. Earlier in his career, Mr. Lowrance was Vice President and Chief Financial Officer of Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, where he oversaw all aspects of finance and accounting, business and growth strategy, and product development. Mr. Lowrance holds a CPA and has a B.B.A. in Accounting from the University of Georgia.

Mr. Lutz has served as Savara’s Chief Operating Officer since February 2023. He has nearly two decades of operational leadership experience in the pharmaceutical industry including business development deal execution, capital markets and finance strategy, and commercial analytics in support of rare disease launches. Prior to joining Savara, Mr. Lutz was Chief Financial and Business Officer of iBio, Inc., and prior to that he served as Chief Financial Officer of Strongbridge Biopharma plc. (having previously served as the company’s Chief Business Officer). Prior to that, Mr. Lutz held leadership roles of increasing responsibility at Shire Plc., and Cinergy Corp. Earlier in his career, he worked as an analyst at Alan B. Slifka and Co. and Goldman Sachs. Mr. Lutz holds a B.A. in economics and computer science from Amherst College and an M.B.A. from the Kellogg School of Management.

Mr. Parker has served as Savara’s Chief Commercial Officer since September 2024. With more than 25 years of experience in the healthcare and biotech industry, Mr. Parker is a seasoned commercial leader who has developed and executed global commercial plans, built high-performance teams, and launched multiple successful rare disease products. Previously, Mr. Parker was the Chief Commercial Officer at Orchard Therapeutics (Kyowa Kirin) where he was responsible for global commercial strategy, including overseeing Orchard Therapeutics’ first product launch. Prior to that, Mr. Parker served as Vice President and General Manager for the U.S. organization for PTC Therapeutics and led the company’s first U.S. product launch. Earlier in his career, Mr. Parker held commercial leadership roles at Celgene and NPS Pharma (Shire). Mr. Parker holds an M.B.A. from New York University Stern School of Business and a B.B.A. from the University of Notre Dame.

Dr. Pratt has served as Savara’s Chief Medical Officer since November 2022. He was most recently the Chief Medical and Chief Development Officer at Rockwell Medical Inc. Dr. Pratt is an accomplished senior executive and physician with more than 35 years of clinical medicine and drug development experience in global pharmaceutical and device industries. Previously, Dr. Pratt held senior roles at Eisai America, Shire Pharmaceuticals, and Quintiles Transnational. His expertise includes clinical research, regulatory affairs, clinical pharmacology and data analytics. Dr. Pratt has more than 40 peer reviewed publications and has contributed to multiple NDA, MAA and NDS applications in the fields of neurology, psychiatry, hematology, and nephrology. He received a M.D. from University of Illinois College of Medicine and a B.A. in Chemistry from Northwestern University.

Dr. Advant has served as Savara’s Executive Vice President, Global Technical Operations since March 2024. With approximately three decades of experience in the biopharmaceutical sector, he has considerable expertise in drug substance, drug product, and analytical development with early- and late-stage clinical and commercially approved biologics. Dr. Advant also has extensive expertise in technology transfer, scale-up and cGMP manufacturing (both internal and external) in a highly regulated environment. To date, Dr. Advant has helped launch multiple biologic assets across several therapeutic areas. Prior to joining Savara, he was VP, Manufacturing Operations at GSK, where he was responsible for multi-site drug substance and drug product operations. Previously he held roles of increasing responsibility at Celgene Corporation (acquired by Bristol Myers Squibb), Kemwell BioPharma, ImClone/Lilly, and Diosynth Biotechnology (now FujiFilm Diosynth Biotechnolgy), among others. Dr. Advant holds a Ph.D. in Pharmaceutics from the University of Connecticut.

Mr. LaPree is Savara’s Senior Vice President of Global Regulatory Affairs, having previously served as Savara’s Senior Vice President, Global Regulatory Affairs and Quality Assurance. He has more than three decades of domestic and international drug development experience encompassing all aspects of global Regulatory Affairs and Quality Assurance. Prior to joining Savara, Mr. LaPree was SVP, Head of Global Regulatory Affairs and Quality Assurance at Annexon Biosciences. Prior to that he was VP, Head of Global Regulatory Affairs and Medical Writing at Astex Pharmaceuticals and previously served as SVP, Head of Global Regulatory Affairs at Jazz Pharmaceuticals. Mr. LaPree has held leadership roles of increasing responsibility at several other companies, including Shire Pharmaceuticals, Bristol-Myers Squibb Company, and Johnson & Johnson. He holds a B.S. in Chemistry from Rochester Institute of Technology and a M.S. in Environmental Sciences from the University of Rochester School of Medicine and Dentistry.

Ms. McCabe has served as Savara’s General Counsel since December 2022 and Head of Legal Affairs since March 2018. Prior to joining Savara, Ms. McCabe practiced corporate and securities law at Wilson Sonsini Goodrich & Rosati, Professional Corporation, where she represented life sciences and technology companies in a variety of matters, including entity formation and structuring, venture capital financings, corporate governance, mergers and acquisitions, public offerings, public company disclosure requirements, and SEC compliance matters. Ms. McCabe holds a B.S. in Accounting from Canisius College and a J.D. from the University of Texas School of Law.